Filing Details
- Accession Number:
- 0001415889-23-006833
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-25 16:09:58
- Reporting Period:
- 2023-04-21
- Accepted Time:
- 2023-04-25 16:09:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070081 | Ptc Therapeutics Inc. | PTCT | Pharmaceutical Preparations (2834) | 043416587 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1707685 | Marie Christine Utter | C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080 | Svp, Finance & Cao | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-21 | 4,321 | $33.02 | 42,380 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-21 | 4,321 | $55.05 | 38,059 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-04-21 | 371 | $33.02 | 38,430 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-21 | 351 | $55.09 | 38,079 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-04-21 | 20 | $55.64 | 38,059 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-21 | 4,321 | $33.02 | 4,321 | $33.02 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-21 | 371 | $33.02 | 371 | $33.02 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2029-01-21 | No | 4 | M | Direct | |
| 0 | 2029-01-21 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | $51.00 | 2025-01-02 | 17,800 | 17,800 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $51.16 | 2030-01-28 | 23,800 | 23,800 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $66.49 | 2031-01-05 | 50,750 | 50,750 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $38.10 | 2032-01-06 | 43,500 | 43,500 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $39.42 | 2033-01-04 | 32,500 | 32,500 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2025-01-02 | 17,800 | 17,800 | Direct |
| 2030-01-28 | 23,800 | 23,800 | Direct |
| 2031-01-05 | 50,750 | 50,750 | Direct |
| 2032-01-06 | 43,500 | 43,500 | Direct |
| 2033-01-04 | 32,500 | 32,500 | Direct |
Footnotes
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on February 24, 2023.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.
- This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
- Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
- This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.
- This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Billionaire Hedge Funds
